Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study

Table 5 Risk factors associated with 30-d mortality in patients with hepatorenal syndrome

Variable	< 30-d mortalityn (%)	≥30-d mortalityn (%)	Crude OR(95%CI)	Adjusted OR(95%CI)	P value
Age, (yr)
< 65	7 (43.8)	4 (23.5)	1	-
≥ 65	9 (56.2)	13 (76.5)	2.53 (0.57-11.26)
Child-Pugh class
B	5 (31.2)	13 (76.5)	1	11.98 (0.97-148.23)	0.053
C	11 (68.8)	4 (23.5)	7.15 (1.53-33.37)
Sodium
≥ 132 mEq/L	3 (18.8)	10 (58.8)	1
< 132 mEq/L	13 (81.2)	7 (41.2)	6.19 (1.27-30.17)	31.39 (1.54-641.83)	0.020
Total bilirubin
≤ 3.6 mg/dL	4 (25.0)	12 (70.6)	1
> 3.6 mg/dL	12 (75.0)	5 (29.4)	7.20 (1.55-33.56)	0.69 (0.17-28.06)	0.800
Hepatocellular carcinoma
Absent
Present	13 (81.2)	8 (47.1)	1
	3 (18.8)	9 (52.9)	4.88 (1.01-23.57)	1.37 (0.13-14.91)	0.700
MELD score
≤ 27	4 (25.0)	14 (82.4)	1
> 27	12 (75.0)	3 (17.6)	14.0 (2.60-75.41)	18.72 (1.63-214.56)	0.010

Crude and adjusted odds ratio (OR) deriving from multiple logistic regression analysis. CI: Confidence interval; MELD: Model for End stage liver disease.